Evorpacept — Investigational Agent
CD47 Inhibitor · Phase 2/3 · ALX Oncology
Mechanism of Action
A high-affinity CD47-blocking fusion protein: an engineered SIRPα variant domain linked to an inactivated (Fc-dead) human IgG1 Fc. By binding CD47 with picomolar affinity while carrying a Fc engineered to minimize red-cell binding and hematologic toxicity, evorpacept blocks the CD47–SIRPα "don't eat me" signal to enhance macrophage phagocytosis — with substantially less on-target anemia than antibody-based anti-CD47 agents. Designed to be combined with tumor-targeting antibodies (rituximab, trastuzumab, cetuximab) and other standards of care.
Investigational Indications
- HER2-positive gastric / gastroesophageal junction cancer — with trastuzumab-based therapy
- Head and neck squamous cell carcinoma — with pembrolizumab/chemotherapy
- Relapsed/refractory non-Hodgkin lymphoma — with rituximab
- Higher-risk MDS / AML (earlier-phase combinations with azacitidine)